BAC vs ZYME Stock Comparison
ZYME currently leads BAC in this stock comparison, with AIQ scores of 68 vs 58. The clearest difference is momentum, while BAC has the stronger risk resilience profile.
What is the main difference between BAC and ZYME?
ZYME leads the current stock comparison as Zymeworks Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Bank of America Corporation vs Zymeworks Inc.
ZYME leads
ZYME leads by 10 AIQ points, primarily on Momentum, having only recently taken the lead back from BAC.
Fragile: 4 of 6 evidence groups support ZYME, the lead recently changed hands, and its current signal state is conflicted.
Bank of America Corporation
Zymeworks Inc.
The Algovestiq AIQ Score currently favors ZYME over BAC, 68 versus 58 as of Nov 15, 2026. ZYME's advantage is driven primarily by stronger momentum, while BAC holds the stronger risk resilience profile. ZYME also shows the stronger technical structure relative to its 50-day moving average. 4 of 6 covered evidence groups favor ZYME today, and the comparison is rated Fragile on stability: the lead has already changed hands inside the comparison window. ZYME lead: Reversed — BAC led by 11 AIQ points 30 sessions ago; ZYME now leads by 10.
Compare Bank of America Corporation and Zymeworks Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare BAC and ZYME against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum37 vs 78ZYME +41
- Risk Resilience83 vs 61BAC +22
- Quality64 vs 62Even
- Value68 vs 66Even
4 of 6 evidence groups favor ZYME. ZYME’s edge is concentrated in momentum; BAC keeps a meaningful risk resilience edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
No factor moved materially.
New signals
- OBV Bullish Divergence — bullish, volume, medium horizon (-0.4%)
Largest factor move: Risk Resilience +4
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
ZYME's lead widened by 2 AIQ points in the latest session.
Deeper signal detail for each name lives on its own signals page — BAC and ZYME both carry a full feed there.
The central trade-off
ZYME (Zymeworks Inc.): the stronger current systematic profile, led by momentum.
BAC (Bank of America Corporation): the counter-case, on risk resilience.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
ZYMEZYME on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
ZYMEZYME on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
ZYMEZYME on the Momentum factor, by 41 points.
Lower downside
BACBAC on Risk Resilience, by 22 points.
Analyst upside
ZYMEZYME on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | BAC | ZYME | Note |
|---|---|---|---|
| Implied upside to target | +24.1% | +62.3% | ZYME has more room |
| Target dispersion | +25.3% | +54% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 25 | 14 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor ZYME. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | ZYME | 58 vs 68 |
| Fundamentals | ZYMEon balance | revenue growth -3.3% vs 54.9%; EPS growth -23.8% vs 4.9%; TTM ROE 2.3% vs 67.3%; gross margin 60.4% vs 98.3%; operating margin 22.4% vs 16.6% — ZYME takes 4 of 5 decided legs, not all of them |
| Valuation | Even | Value 68 vs 66 |
| Technicals | ZYME | Price vs 50-day -5.6% vs -4%; vs 200-day -7% vs 2.8% |
| Risk Resilience | BAC | Risk Resilience 83 vs 61 |
| Analyst expectations | ZYME | Target upside 24.1% vs 62.3% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BAC and ZYME and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is moderate at 10 points.
- The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
- The lead has swung materially session to session. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ZYME.
How the comparison changed
120 daily snapshots · May 27 – Nov 13ZYME lead: Reversed — BAC led by 11 AIQ points 30 sessions ago; ZYME now leads by 10.
- Today
- ZYME +10
- 58 vs 68
- 7 sessions ago
- ZYME +1
- 58 vs 59
- 30 sessions ago
- BAC +11
- 62 vs 51
- 90 sessions ago
- BAC +21
- 71 vs 50
The lead changed hands once in this window, most recently on Nov 6 when ZYME moved ahead of BAC.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 2 bearish / 1 neutral, conflicted
Only BAC
- Bollinger Band Squeeze — neutral, volatility, short horizon (4.5%)
- Death Cross Active — bearish, trend, long horizon (1.45%)
- Downtrend Structure Active — bearish, trend, long horizon
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
- OBV Bullish Divergence — bullish, volume, medium horizon (-0.4%)
2 bullish / 2 bearish / 2 neutral, conflicted
Only ZYME
- Golden Cross Active — bullish, trend, long horizon (7.04%)
- ADX Trend Weakening — neutral, trend, medium horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (5.44%)
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
- MACD Histogram Expanding Bearish — bearish, momentum, short horizon
ZYME leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.01%, AIQ 0 points).
Price is down while the AIQ Score moved up 2 points over the same session — price and model disagree (price -0.87%, AIQ +2 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1BAC closes the Momentum gap — currently 41 points behind, the largest single contributor to ZYME's edge.
- 2BAC's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3ZYME's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
ZYME leads on balance| Metric | BAC | ZYME |
|---|---|---|
| Revenue growth (YoY) | -3.3% | 54.9% |
| EPS growth (YoY) | -23.8% | 4.9% |
| Gross margin | 60.4% | 98.3% |
| Operating margin | 22.4% | 16.6% |
| Return on equity (TTM) | 2.3% | 67.3% |
| Debt to equity | 1.28 | 2.52 |
Performance
ZYME leads 5 of 6 windows| Metric | BAC | ZYME |
|---|---|---|
| 1 week (5 sessions) | 3.2% | -11.4% |
| 1 month (20 sessions) | -0.4% | 4.8% |
| 3 months (63 sessions) | -20.1% | 3.7% |
| 6 months (126 sessions) | 2.5% | 9.7% |
| Year to date | -7.2% | -0.3% |
| 1 year (252 sessions) | -5.7% | 35.5% |
Technicals
ZYME has the stronger structure| Metric | BAC | ZYME |
|---|---|---|
| RSI (14) | 45.9 | 42 |
| ADX (14) | 27.2 | 23.8 |
| Price vs 50-day | -5.6% | -4% |
| Price vs 200-day | -7% | 2.8% |
| Volatility (1M, annualized) | 24.8% | 63.1% |
Risk
BAC is the more resilient| Metric | BAC | ZYME |
|---|---|---|
| Beta | 0.79 | 0.78 |
| Sharpe ratio | -0.22 | 0.84 |
| Sortino ratio | -0.29 | 1.39 |
| Max drawdown | -23.7% | -23.6% |
| Current drawdown | -21.3% | -16.6% |
| Annualized volatility | 22.4% | 54% |
| Value at risk (95%) | -2.6% | -4.1% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, BAC or ZYME?
On the Algovestiq AIQ Score, ZYME is the stronger of the two as of Nov 15, 2026, scoring 68 against BAC's 58. The edge comes from momentum. BAC is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is BAC or ZYME the better buy right now?
ZYME carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 4 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the lead has already changed hands inside the comparison window. Treat the lead as provisional.
Why does the AIQ Score favor ZYME over BAC?
The composite weights Quality, Value, Momentum and Risk Resilience. ZYME leads Momentum by 41 points; BAC leads Risk Resilience by 22 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, BAC or ZYME?
Analyst price targets imply +24.1% upside for BAC and +62.3% for ZYME, so the Street currently favors ZYME. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, BAC or ZYME?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, BAC or ZYME?
ZYME on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, BAC or ZYME?
ZYME on the Momentum factor, by 41 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, BAC or ZYME?
BAC is the more resilient of the two, so the other name carries the higher downside risk. BAC on Risk Resilience, by 22 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is BAC more profitable than ZYME?
The profitability evidence is mixed: gross margin 60.4% vs 98.3%; operating margin 22.4% vs 16.6%; ttm roe 2.3% vs 67.3%. BAC leads on one measure and ZYME on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is ZYME's lead over BAC getting stronger or weaker?
ZYME lead: Reversed — BAC led by 11 AIQ points 30 sessions ago; ZYME now leads by 10. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands once in that window, most recently on 2026-11-06, when ZYME moved ahead of BAC.
What would change the BAC vs ZYME verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BAC closes the Momentum gap — currently 41 points behind, the largest single contributor to ZYME's edge; BAC's Death Cross Active resolves — a bearish trend rule currently active against it; ZYME's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about BAC and ZYME?
BAC: 2 bullish / 2 bearish / 1 neutral, conflicted. ZYME: 2 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BAC is Death Cross Active (bearish, long horizon). On ZYME it is Golden Cross Active (bullish, long horizon).
Compare BAC and ZYME with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.